Clinical trials: QTc Interval
Healthy
Effects of Single Oral Dose Dapagliflozin QT Study
The main purpose of this study is to examine the effect of dapagliflozin on electronic measures of heart beats in healthy males
- Trial name
- NCT00688493
- Testing
- Dapagliflozin, Moxifloxacin
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers
To assess the safety of cangrelor on cardiac repolarization as measured by electrocardiogram (ECG) at therapeutic and supratherapeutic doses.
- Trial name
- NCT00699504
- Testing
- cangrelor, moxifloxacin
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- The Medicines Company
Healthy
A TQT Study of Effect of M2951 on Cardiac Repolarization
The purpose of this study is to assess potential effects of M2951 on cardiac repolarization (i.e. prolongation of QT interval).
- Trial name
- NCT07214935
- Testing
- Moxifloxacin, M2951 Low Dose, M2951 High Dose
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
TQT Study
A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects
This is a randomized, double-blind (with respect to Tebipenem pivoxil hydrobromide [TBPM-PI-HBr]/placebo only), placebo- and active-control, single-dose, 4-way crossover study that will enroll 24 healthy adult male and female…
- Trial name
- NCT04238195
- Testing
- Moxifloxacin 400mg, Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Spero Therapeutics
Healthy
Evaluation of the Effect of ATX-101 on QT/QTc Intervals
To evaluate the effect of maximum therapeutic and supratherapeutic doses of ATX-101 treatment on Fridericia's corrected QT interval (QTcF).
- Trial name
- ATX-101-11-24 (NCT01706679)
- Testing
- ATX-101 (10 mg/ml), ATX-101 (20 mg/ml), Moxifloxacin (400 mg)
- Where
- United States
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals
Healthy Volunteer
A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers
This multiple-center, multiple-dose, randomized, double-blind, double-dummy, placebo-controlled, positive-controlled, parallel group study will investigate the effect of RO4917838 on the QTc interval in healthy volunteers.
- Trial name
- NCT01613040
- Testing
- Moxifloxacin, RO4917838
- Where
- 2 sites in United States, France
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy
A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects
This is a Phase I, single-site, randomized, double-blinded, double-dummy, placebo- and positive-controlled, 4-period crossover study to evaluate the effect of two dose levels of Androxal on cardiac repolarization.
- Trial name
- NCT02117830
- Testing
- Androxal 25 mg capsules, Androxal 250 Capsules, Moxifloxacin 400 mg
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Repros Therapeutics Inc.
Healthy Subjects
To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.
This is a single-center, randomized, double-blind for cenerimod, open-label for moxifloxacin, placebo- and moxifloxacin-controlled, parallel-group study to investigate the effect of cenerimod on the duration of the QT interval in…
- Trial name
- NCT04255277
- Testing
- Combined oral contraceptives (COC), Moxifloxacin 400mg, Cenerimod 0.5 mg
- Where
- France
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Viatris Innovation GmbH
Hypertension
VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
The purpose of this study is to evaluate the safety,tolerability,pharmacokinetics and pharmacodynamics of VB19055 in the healthy Chinese population.
- Trial name
- NCT07254481
- Testing
- VB19055
- Where
- 2 sites in China
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Bacterial Infections
A Study To Assess The Effect Of Linezolid On QTc Interval
The FDA has asked Pfizer to assess the risk of linezolid on QT interval (obtained from ECG readings) which could predispose patients to ventricular arrhythmias. This study is conducted to satisfy this requirement.
- Trial name
- NCT00795145
- Testing
- Linezolid 900 mg, Linezolid 1200 mg, Linezolid 600 mg
- Where
- Singapore
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Person
ZL-82 Double-blind Clinical Trial
ZL-82 tablets are highly selective covalent irreversible inhibitors of non-receptor tyrosine protein kinase 3 (Janus kinase 3, JAK3) developed by Chengdu Zenitar Biomedical Technology Co., Ltd. According to Document No.
- Trial name
- NCT06432738
- Testing
- ZL-82
- Where
- China
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Healthy Volunteer
An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001
This a phase 1, partially blinded, randomized, crossover study to determine the pharmacokinetics (PK) and QT/QTc interval of study drug (ESK-001) in healthy volunteer participants,
- Trial name
- NCT07378579
- Testing
- ESK-001, Moxifloxacin (400 mg)
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Alumis Inc
Human Experimentation (Human Volunteers)
Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers
This phase I trial will evaluate the effects of rupatadine, at a dose of 10 mg OD (authorised and marketed dose) and the 100mg/day (supratherapeutic dose) on the ECG parameters with a special focus on its effect on cardiac…
- Trial name
- NCT00199225
- Testing
- Rupatadine, moxifloxacin, Continous electrocardiographic register
- Where
- Spain
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- J. Uriach and Company
Anxiety Disorders
Concentration-QT Study of Paroxetine in Healthy Adults
The primary purpose of the study is to evaluate the potential effect of paroxetine on QTc interval following escalating doses in healthy participants.
- Trial name
- NCT06065735
- Testing
- Paroxetine
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers - Male and Female
A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults
This is a Phase 1, single-center, randomized, single-blind (participants are blinded), placebo controlled, four-way cross over TQT study (4×4 Williams square design) to investigate the effect of KP-001 on the QTc interval using…
- Trial name
- NCT06649942
- Testing
- KP-001, Moxifloxacin 400 mg
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kaken Pharmaceutical
Prolonged QTc Interval, Pharmacokinetic
Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women
The effect of multiple oral administration of two doses of CG5503 PR (prolonged release) compared to placebo on the electrical activity of the heart were investigated.
- Trial name
- NCT03951402
- Testing
- 100 mg CG5503 (tapentadol hydrochloride) PR tablet, 400 mg Moxifloxacin tablet (overencapsulated)
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH
Mandibular Prognathism, Mandibular Retrognathism
The Effect of Deliberate Hypotension on QTc, Tp-e Intervals and Heart Rate Variability
Deliberate hypotension is defined as lowering the systolic blood pressure to 80-90mmHg, or the mean blood pressure to 50-65mmHg.
- Trial name
- NCT01634594
- Testing
- Group R, Group N, Group D
- Where
- South Korea
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Healthy Volunteers
A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects
This study is primarily to evaluate the single dose pharmacokinetics of CP-751,871 and its effect on QT interval prolongation.
- Trial name
- NCT00926263
- Testing
- CP-751,871, CP-751,871, moxifloxacin, saline
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subjects
A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects
This thorough QT (TQT) study will take place in healthy subjects administered single doses of study drug. It will be a randomized, double-blind, placebo and active-controlled, 4-treatment crossover study.
- Trial name
- NCT02222324
- Testing
- E2609, Moxifloxacin
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Infections, Bacterial
A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.
GSK945237 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of antibiotics. GSK945237 has demonstrated in vitro and in vivo activity against Gram positive [including methicillin resistant Staphylococcus aureus…
- Trial name
- NCT01039610
- Testing
- GSK945237, Linezolid, Moxifloxacin
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline